No Data
No Data
Trump Targets Medicare Price Negotiations in New Executive Order
Goldman Sachs Adjusts Price Target on Amgen to $400 From $408, Maintains Buy Rating
Uncertainty looms, which biotech stocks in the U.S. are expected to break through? Goldman Sachs provides the answer.
Goldman Sachs suggests focusing on companies that are less affected by tariffs and policy risks, such as Vertex Pharmaceuticals (VRTX.US) and Alnylam Pharmaceuticals (ALNY.US).
The Trump administration has initiated a "tariff investigation" in the pharmaceutical sector, and the "safe haven" appeal of Indian pharmaceutical stocks has almost completely disappeared.
Indian pharmaceutical stocks are facing a large-scale sell-off, impacted by the dual blows of the Trump tariff investigation and a slowdown in capital flow.
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $350
UBS Maintains Amgen(AMGN.US) With Hold Rating, Cuts Target Price to $319